

**Supplemental Table. Baseline characteristics of unmatched and matched cohorts using abatacept or an anti-TNF with follow-up at 12 months.**

	Unmatched		P value	Matched		P value
	ABA N=327	Anti-TNF N=637		ABA N=311	Anti-TNF N=493	
<b>Demographics</b>						
Age (mean age, SD)	57.5 (12.6)	56.0 (12.3)	0.075	57.30 (12.6)	56.97	0.703
Gender (% female)	79.2	80.0	0.800	79.42	79.11	0.929
Race (% white)	81.7	84.1	0.362	81.99	82.56	0.850
<b>Insurance (%)</b>						
Private	78.0	78.2	1.000	78.46	79.72	0.721
Medicare	38.5	31.6	0.041	37.94	31.91	0.093
Medicaid	5.5	6.8	0.479	5.79	6.50	0.765
<b>Clinical</b>						
RF Seropositivity (%)	72.9	76.9	0.281	72.33	76.72	0.298
Disease duration (mean years, SD)	13.9 (10.2)	11.8 (9.3)	0.001	13.6 (9.8)	12.1 (9.7)	0.034
Tender joints, n (SD)	7.5 (7.2)	7.0 (6.7)	0.365	7.4 (7.2)	7.0 (6.7)	0.464
Swollen joints, N (SD)	6.9 (6.1)	6.0 (5.4)	0.020	6.7 (5.9)	6.0 (5.1)	0.069
Patient pain score (mean, SD)	50.0 (25.7)	48.4 (25.6)	0.357	50.1 (25.8)	48.6 (25.7)	0.415
mHAQ (mean, SD)	0.6 (0.5)	0.6 (0.5)	0.106	0.6 (0.5)	0.6 (0.5)	0.115
CDAI (mean, SD)	22.7 (14.2)	21.2(12.8)	0.097	22.5 (14.1)	21.1 (12.5)	0.152
<b>Disease activity* (%)</b>						
Low	22.6	21.0		22.8	20.3	
Moderate	34.6	38.2		34.7	38.3	
High	42.8	40.8		42.4	41.4	
<b>Concomitant medications</b>						
Corticosteroids, (%)	39.1	33.8	39.1	38.9	32.9	0.082
Leflunomide, (%)	11.9	13.5	11.9	12.2	13.4	0.667
MTX, (%)	52.3	56.8	52.3	52.1	57.8	0.126
Dose, mg/week (SD)	16.1 (6.4)	16.2 (6.1)	16.1	16.2 (6.5)	16.2 (5.9)	0.979